Funds hit jackpot in $2b UK biotech deal
SYDNEY: Swiss pharmaceutical giant Novartis has agreed to pay more than $2 billion for early-stage
SYDNEY: Swiss pharmaceutical giant Novartis has agreed to pay more than $2 billion for early-stage